Evidence map›Paper›PMID 39071569›Full record

ArticleHeliyon2024

Highly consistency of

Yan Liu, Hui Li, Xiang Li, Tingting Zhang, Yang Zhang, Jing Zhu, Heran Cui, Rixin Li, Ying Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan LiuTranslational Oncology Research Lab Jilin Province, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, China.
Hui LiTranslational Oncology Research Lab Jilin Province, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, China.
Xiang LiTranslational Oncology Research Lab Jilin Province, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, China.
Tingting ZhangDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, China.
Yang ZhangDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, China.
Jing ZhuDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, China.
Heran CuiBiobank, Jilin Cancer Hospital, Changchun, 130012, China.
Rixin LiBiobank, Jilin Cancer Hospital, Changchun, 130012, China.
Ying ChengTranslational Oncology Research Lab Jilin Province, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Methods: Circulating tumor DNA (ctDNA) and matched tumor tissue samples from 405 advanced lung cancer patients were collected at Jilin Cancer Hospital between 2018 and 2022, and the Results: Conclusion: This study showed that ctDNA is highly concordant and sensitive for identifying

Indexed as

ctDNALung cancerNGSPIK3CATissue

Identifiers

PMID39071569
PMCPMC11277437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.